Eculizumab Treatment in Severe Pediatric STEC-HUS: a Multicenter Retrospective Study

Lucas Percheron, Raluca Gramada,Stéphanie Tellier,Remi Salomon,Jérôme Harambat,Brigitte Llanas,Marc Fila,Emma Allain-Launay,Anne-Laure Lapeyraque,Valerie Leroy, Anne-Laure Adra,Etienne Bérard,Guylhène Bourdat-Michel, Hassid Chehade,Philippe Eckart,Elodie Merieau,Christine Piètrement,Anne-Laure Sellier-Leclerc,Véronique Frémeaux-Bacchi,Chloe Dimeglio,Arnaud Garnier

Pediatric nephrology（2018）

引用 37|浏览15

暂无评分

摘要

Hemolytic uremic syndrome related to Shiga-toxin-secreting Escherichia coli infection (STEC-HUS) remains a common cause of acute kidney injury in young children. No specific treatment has been validated for this severe disease. Recently, experimental studies highlight the potential role of complement in STEC-HUS pathophysiology. Eculizumab (EC), a monoclonal antibody against terminal complement complex, has been used in severe STEC-HUS patients, mostly during the 2011 German outbreak, with conflicting results.

查看译文

关键词

Hemolytic uremic syndrome,Acute kidney injury,Pediatric,Complement

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要